The problem of immune thrombocytopenia refractory to both eltrombopag and romiplostim.

Al-Samkari, Hanny; Schifferli, Alexandra; Gonzalez-Lopez, Tomas J

Al-Samkari, Hanny; Schifferli, Alexandra; Gonzalez-Lopez, Tomas J.

Afiliação

Al-Samkari H; Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Schifferli A; Department of Hematology/Oncology, University Children's Hospital Basel, Basel, Switzerland.
Gonzalez-Lopez TJ; Hematology Department, Hospital Universitario de Burgos, Burgos, Spain.

Br J Haematol ; 204(4): 1143-1145, 2024 Apr.

Article em En | MEDLINE | ID: mdl-38319005

ABSTRACT

ABSTRACT

Immune thrombocytopenia refractory to multiple thrombopoietin receptor agonists remains a challenging clinical problem. This commentary discusses and contextualizes the recent report on this entity from Moulis and colleagues, and how to move forward with these patients. Commentary on Moulis et al. Difficult-to-treat primary immune thrombocytopenia in adults Prevalence and burden. Results from the CARMEN-France Registry. Br J Haematol 2024;2041476-1482.

Assuntos

Púrpura Trombocitopênica Idiopática; Pirazóis; Trombocitopenia; Adulto; Humanos; Púrpura Trombocitopênica Idiopática/tratamento farmacológico; Receptores de Trombopoetina/agonistas; Trombocitopenia/tratamento farmacológico; Trombopoetina/uso terapêutico; Benzoatos/uso terapêutico; Hidrazinas/uso terapêutico; Receptores Fc/uso terapêutico; Proteínas Recombinantes de Fusão/uso terapêutico

Palavras-chave

eltrombopag; immune thrombocytopenia; refractory; romiplostim; thrombopoietin receptor agonist

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazóis / Trombocitopenia / Púrpura Trombocitopênica Idiopática Tipo de estudo: Risk_factors_studies Limite: Adult / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google